CLINICAL TRIAL FOR CANINE INTRANASAL ADENOCARCINOMA

October 27th, 2022 Posted by Oncology 0 thoughts on “CLINICAL TRIAL FOR CANINE INTRANASAL ADENOCARCINOMA”

Enrollment COMING SOON! December 2022

ACI will soon begin enrolling patients in a multicenter, randomized, double-masked, placebo-controlled clinical trial to evaluate a novel investigational product in dogs with stage 3 intranasal adenocarcinoma.


Participation Requirements

  • Patients will receive radiation therapy and investigational product or placebo intravenously under general anesthesia for 5 consecutive days.
  • Patients will be required to visit study site for regularly scheduled appointments over a 4-month period.
  • Owners will be required to document study associated observations and questionnaires as appropriate.


Study Benefits

  • If you elect to enroll your dog in the study, the investigational drug will be funded at no charge to you.
  • The study site will discuss the other veterinary services that are covered at no cost to you if your pet is eligible.


Eligibility Criteria

  • Dog is ≥ 12 months of age
  • Dog weighs > 5kg
  • Dog has ECOG performance status less ≤ 1
  • Dog has stage 3 intranasal adenocarcinoma and is amenable to radiotherapy
  • Dog is able to tolerate multiple anesthesia events
  • No prior radiotherapy, chemotherapy, or surgical therapy prior to enrollment
  • No clinically significant cardiovascular arrhythmias

The Veterinary Investigator at the study site will determine if your pet meets other eligibility criteria and may enroll in the study.


Study Sites

Ames, IA
Champaign-Urbana, IL
Columbus, OH
Gainesville, FL
Houston, TX
Manhattan, KS
Tucson, AZ
West Lafayette, IN

 


 

If interested in enrolling your pet on this study, please contact ACI by completing the section below.

  • This field is for validation purposes and should be left unchanged.

Coming Soon

Equine Lameness Study

Stay tuned for more information and enrollment.

Veterinarians interested in joining our network of professionals in clinical trials, contact us for more details.